Saturday, June 24, 2017 4:50:18 PM
1) I think the partnership can be either/both PD-L1 or/and PD-1. Here's an interesting research related to this topic:
"A 2015 review of all studies published on PD-1/ PD-L1 blockade showed that approximately 15% of patients with PD-L1–negative tumors responded to anti-PD-1 therapy. While this was significantly lower than the response rate in patients who had PD-L1–positive tumors (45%), Topalian stated that PD-L1 status alone is insufficient to exclude patients from receiving anti-PD-1/PD-L1 therapy."
http://www.onclive.com/publications/oncology-live/2016/vol-17-no-14/biomarker-combos-may-hold-key-to-antipd1pdl1-therapy-response
I have thought that AZ may be the partner but I'm leaning more towards BMS now for these reasons:
a) The COO hire. As I've said when the hire was announced, she has the pedigree to go anywhere. Why go to VBL? It has limited funds. It is a small company HQ'ed in Israel. Basically, her strengths don't match well with the company's current needs. Unless ... something else is going on here between BMS and VBL. We shall see but I think BMS is going to be the partner.
b) BMS (Opdivo) lost big time to Merck (Keytruda) - it lost 20% of its market cap when the failed data was announced. So it's taking a shotgun approach (with its significant resources) to get back in the $15B market that is lost out on to Merck. If not NSCLC, BMS can be targeting VB-111 for glioblastoma or other solid tumors (check out this summary of where BMS is involved: http://info.evaluategroup.com/rs/607-YGS-364/images/epv-pdct17.pdf)
2) I think the big pharma will foot the bill. But a what cost? Dror is not going to give the business away no matter what the COO recommends. I get a feeling she will be negotiating as much for BMS as she will for VBL. Basically with her inside VBL, BMS gets a view to which no other big pharma has. She will know exactly what BMS is looking for and look to determine how strongly VBL fits with BMS's needs.
3) If big pharma foots the bill then why not start? It is something that VBL wants to do but has put off due to limited budget, imo. VBL is at a point at which it wants to discover other capabilities of VB-111 (now that multiple trials have indicated that VB-111 is safe in combo and comes with limited AEs).
As for the timing of the interim report. It will take some time to prepare, analyze and approve the interim data before reporting out. So I think interim will be triggered in Aug/Sep but we won't hear about it until Sep/Oct.
Recent VBLT News
- Form 8-K - Current report • Edgar (US Regulatory) • 09/19/2024 08:05:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/16/2024 08:05:19 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 08/29/2024 08:06:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/26/2024 08:34:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2024 08:31:04 PM
- Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 08/09/2024 08:01:56 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/06/2024 09:20:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/24/2024 11:40:12 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/19/2024 08:05:36 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 07/01/2024 09:19:40 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 06/20/2024 09:01:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/10/2024 09:18:35 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/10/2024 09:17:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/10/2024 09:12:59 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/10/2024 09:07:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/10/2024 09:06:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/10/2024 09:04:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2024 08:30:44 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 04/19/2024 08:56:08 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/12/2024 12:44:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 04/11/2024 09:00:40 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/09/2024 09:20:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/08/2024 04:15:14 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 04/01/2024 08:30:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2024 01:00:14 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM